Roche Holding AG (RHHBF)

OTCMKTS · Delayed Price · Currency is USD
372.05
-11.11 (-2.90%)
Oct 17, 2025, 2:53 PM EDT
-2.90%
Market Cap306.97B
Revenue (ttm)79.83B
Net Income (ttm)11.86B
Shares Outn/a
EPS (ttm)14.77
PE Ratio25.89
Forward PE15.01
Dividend10.97 (2.95%)
Ex-Dividend DateMar 28, 2025
Volume19
Average Volume371
Open368.00
Previous Close383.16
Day's Range365.45 - 381.00
52-Week Range280.85 - 395.28
Beta0.18
RSI52.95
Earnings DateOct 20, 2025

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]

Sector Healthcare
Founded 1896
Employees 103,249
Stock Exchange OTCMKTS
Ticker Symbol RHHBF
Full Company Profile

Financial Performance

In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.

Financial numbers in CHF Financial Statements

News

Roche Wins CHMP Support For Gazyva/Gazyvaro For Lupus Nephritis Treatment

(RTTNews) - Roche Holding AG (RHHBY.PK), Friday announced the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Gazyva/Gazyvaro in comb...

2 days ago - Nasdaq

CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for lupus nephritis

Basel, 17 October, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

2 days ago - GlobeNewsWire

The Zacks Analyst Blog Highlights NVIDIA, Roche, Lam Research, Tredegar and Kewaunee Scientific

NVIDIA, Roche, and Lam Research lead this week's top Zacks research picks, while Tredegar and Kewaunee Scientific highlight strong niche and microcap opportunities.

2 days ago - Nasdaq

Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two Chinese drug developers have signed licensing deals that could yield as much as US$2.5 billion in performance-based payments, underscoring growing international confidence in China’s life sciences...

2 days ago - South China Morning Post

China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal cancer and other...

2 days ago - Reuters

Top Stock Reports for NVIDIA, Roche & Lam Research

NVIDIA, Roche, and Lam Research lead today's top Zacks reports, showcasing standout growth drivers and sector-specific strengths.

2 days ago - Nasdaq

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)

BALA CYNWYD, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...

2 days ago - GlobeNewsWire

Roche (RHHBY) Launches Discount Program for Flu Drug Xofluza

Roche (RHHBY) Launches Discount Program for Flu Drug Xofluza

2 days ago - GuruFocus

Roche to sell flu pill for $50 to cash-paying US patients

Roche on Thursday launched direct-to-consumer U.S. sales of its influenza antiviral pill Xofluza at a discounted cash price of $50, following similar moves by rivals as they scramble to address pressu...

2 days ago - Reuters

Genentech to sell flu pill directly to some consumers at a discount as Trump pressures drugmakers

Roche's Genentech said it will sell its flu pill, Xofluza, directly to certain patients at a discount in a bid to expand access to uninsured people, those with limited coverage or people whose plans d...

2 days ago - CNBC

Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the company's first Direct-to-Patient (DTP) program. This program, wh...

2 days ago - Business Wire

Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025

Basel, 16 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented major updates on its innovative sequencing by expansion (SBX) technology at the American Society of Human Genetics (ASHG) 2025 Ann...

3 days ago - GlobeNewsWire

Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?

Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.

4 days ago - Nasdaq

Wall Street Breakfast Podcast: Papa John's Delivers A Hot Slice

Papa John's soars after report of takeover offer. Roche, Eli Lilly Alzheimer's blood diagnostic test wins FDA approval. Japanese payment app PayPay valuation to likely exceed $20B in US IPO.

5 days ago - Seeking Alpha

Eli Lilly (LLY) and Roche's Blood Test for Alzheimer's Gets FDA Nod

Eli Lilly (LLY) and Roche's Blood Test for Alzheimer's Gets FDA Nod

5 days ago - GuruFocus

Roche Holding's Blood-Based Alzheimer's Test Wins US FDA Approval

(RTTNews) - Roche Holding AG (RHHBY.PK), Monday announced that the U.S. Food and Drug Administration has cleared its Elecsys pTau181 test, a blood-based Alzheimer's test indicated as an aid in the ini...

5 days ago - Nasdaq

Roche, Lilly's blood test for Alzheimer's diagnosis gets US approval

Roche Diagnostics said on Monday the U.S. Food and Drug Administration cleared its and partner Eli Lilly's blood test as an aid in the initial assessment for Alzheimer's disease.

5 days ago - Reuters

Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology

Rules out Alzheimer's pathology in early stages to enhance diagnostic pathway efficiency Provides new opportunity to broaden access and improve referral quality Features as part of Roche's growing por...

6 days ago - PRNewsWire

Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present more than 30 abstracts across more than 10 cance...

6 days ago - Business Wire

Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types

Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (E...

6 days ago - GlobeNewsWire

Roche setback in Delhi HC paves way for cheaper spinal muscular atrophy (SMA) drug

The Delhi High Court has dismissed Roche's appeal, allowing Natco to launch a generic version of Risdiplam for spinal muscular atrophy. This decision prioritizes public health and patient access over ...

9 days ago - The Times of India

HC bins Roche's injunction plea, allows generic version of only drug for SMA

India News: A division bench of Delhi high court Thursday rejected the appeal of pharma giant, Roche, seeking an injunction against Indian pharma company Natco Ph.

9 days ago - The Times of India

Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market

Roche has a promising GLP-1 drug that is entering phase 3 trials.

10 days ago - The Motley Fool